CareAcross is a community for anyone affected by cancer. It is private, free to join, and full of people who understand
Sign in to CareAcross
If you already have an account at CareAcross, please sign in
SIGN UP
CareAcross is a community open to anyone affected by cancer: a private and safe place to share practical tips and personal experiences.
By joining you can also find answers to questions, provided by experienced doctors - and even ask your own question.
SOMETHING WENT WRONG
Email Error
If you already have an account at CareAcross, please sign in
Every year, the largest cancer conference delivers new research and hope for cancer patients worldwide - and this year's is no exception. In this article we provide details on a significant breast cancer finding, straight from Chicago.
Fiona Nielsen is working 24/7 to promote efficient and ethical human genomic data sharing. She recently published a very interesting article on the need to modernise the "consent form".
Professor Håkan Mellstedt is a medical oncologist at the Cancer Center Karolinska in Sweden, with extensive clinical and academic experience. In this article, Prof. Mellstedt, also a member of our Scientific Committee, explains the basics of immunotherapy and key research being conducted across cancer types.
A session at the 2014 ASCO meeting focused on targeted adenocarcinoma treatment for specific genetic mutations-a promising option for some lung cancer patients.
At the European Lung Cancer Conference, new information on lung cancer incidence, key factors and genetic mutations were discussed. We present the highlights.
Genetic analysis is an emerging field of cancer research.
For ovarian cancer, such research can lead to better prevention and more effective treatments.
Our Chief Medical Officer provides the latest details.
Statins are normally used to lower cholesterol (which is seemingly irrelevant to prostate cancer). However, cholesterol controls pathways related to prostate cancer cells’ survival.
In article, our Chief Medical Officer describes the potential benefit to prostate cancer patients, based on two recently published studies.
Adenocarcinoma is the most common type of non-small cell lung cancer. Our Chief Medical Officer explains the benefits from the latest research on targeted drugs.